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Abstract
The mTOR/S6K1 signaling pathway controls cell growth and proliferation. To assess the
importance of S6K1 in the balance between death and survival in the liver, we have generated
immortalized hepatocyte cell lines from wild-type and S6K1-deficient (S6K1−/−) mice. In
S6K1−/− hepatocytes caspase-8 and the pro-apoptotic protein Bid were constitutively down-
regulated as compared to wild-type. Moreover, S6K1−/− hepatocytes failed to respond to the
apoptotic trigger of death receptor activation. Neither caspase-8 activation nor FLIPL degradation
in response to TNFα or anti-Fas antibody (Jo2) was observed in cells lacking S6K1. Downstream
events such as Bid cleavage, cytochrome C release, caspase-3 activation, DNA laddering, as well
as the percentage of apoptotic cells were attenuated as compared to wild-type. In addition, the
anti-apoptotic protein BclxL was down-regulated in TNFα or Jo2-treated wild-type hepatocytes,
but this response was abolished in S6K1−/−cells. In vivo, S6K1-deficient mice were protected
against concanavalin A-induced apoptosis. The withdrawal of growth factors strongly induced
apoptosis in wild-type, but not in S6K1−/− hepatocytes. S6K1 deficiency did not decrease BclxL/
Bim ratio upon serum withdrawal, thereby protecting cells from cytochrome C release and DNA
fragmentation. At the molecular level, the lack of S6K1-mediated negative feed-back decreased
IRS-1 serine phosphorylation resulting in activation of survival pathways mediated by
phosphatidylinositol 3-kinase (PI 3-K)/Akt and ERK. However, S6K1−/− hepatocytes underwent
apoptosis upon serum withdrawal in combination of PI 3-K or ERK inhibitors. This finding might
explain the mechanism of resistance to mTOR inhibitors in cancer treatments, and strongly
suggests that the inhibition of S6K1 could protect against acute liver failure and, in combination
with inhibitors that abrogate the sustained activation of Akt and ERK, could improve the efficacy
of hepatocarcinoma (HCC) treatment.
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INTRODUCTION
Apoptosis mediated via extrinsic or intrinsic pathways is essential for maintaining cellular
homeostasis in the liver. In this tissue, binding of FasL or inflammatory cytokines, such as
TNF-α, to death receptors on the cell surface (Fas, TNF-R1) induces the extrinsic apoptotic
pathway by the recruitment of adapter proteins (FADD, TRADD) and procaspases -8 and
-10 at the intracellular domain of the receptor to form the death-inducing signalling complex
(DISC) (1). The signal generated at the DISC by activated caspases leads to cell death,
which, depending on the cell type, may or may not require mitochondrial involvement for its
execution (2). The intrinsic pathway is triggered by extracellular and intracellular stress
signals, such as growth factors withdrawal, hypoxia, DNA damage, and oncogene induction
resulting in the permeabilization of the outer mitochondrial membrane and the release of
cytochrome C and other proapoptotic molecules. These events lead to the formation of the
apoptosome followed by activation of the executer caspase-3 (3). Deregulation of apoptosis
pathways contributes to diseases such as hepatocellular carcinoma (HCC), viral and
autoimmune hepatitis, ischemia and reperfusion injury, toxic liver damage and acute liver
failure (4).
Among the most important survival factors in the liver are several receptors of tyrosine
kinases (TRK) activated by growth factors, such as epidermal growth factor (EGF),
fibroblast growth factors (FGFs), and hepatocyte growth factor (HGF). In addition, the
protective role of insulin against apoptosis induced by both extrinsec and intrinsic pathways
has been reported in neonatal hepatocytes (5,6). At the molecular level, phosphatidylinositol
3-kinase (PI 3-K)/Akt signaling represents a major survival pathway. Its activation has been
associated with malignant transformation and apoptotic resistance (7). Downstream of Akt,
the mammalian target of rapamycin (mTOR) plays a central role in regulating cell growth,
proliferation and survival, in part by regulation of translation initiation (8).
mTOR resides in two different multiprotein complexes: the rapamycin-sensitive mTOR
complex 1 and the rapamycin-insensitive mTOR complex 2. In mTOR complex 1, mTOR
interacts with the regulatory-associated protein of mTOR (raptor), G-protein β-subunit-like
protein (Gβl) and proline-rich PKB/Akt substrate 40 kDa (PRAS40). In response to mitogen
stimulation, mTOR phosphorylates and activates S6K1, which in turn phosphorylates the
40S ribosomal protein S6, leading to the enhancement of translation of mRNAs with a 5′-
terminal oligopyrimidine, including mRNAs that encode for ribosomal proteins and
elongation factor-1. Rapamycin and its derivates RADD001 (Novartis) and CCI-779 (Wyeth
Ayerst) are presently undergoing clinical trials for the treatment of solid tumours including
HCC (9). These compounds block mTOR signaling by forming an inhibitory complex with
the immunophilin FKBP12, which binds to and inhibits the ability of mTOR to
phosphorylate downstream targets such as S6K1. The importance of mTOR as a therapeutic
target in the treatment of HCC is based on the strong anti-tumoral effect of mTOR inhibition
in an experimental model of HCC (10) and, more importantly, on the activation of the
mTOR/S6K1 pathway observed in human HCC (11). However, the specific role of S6K1 in
the regulation of the balance between death and survival in cells of the liver remains
unexplored.
In the present study we have investigated the molecular mechanism by which S6K1
deficiency alters susceptibility to apoptosis in hepatocytes. As a cellular model, we have
developed immortalized neonatal hepatocyte cell lines from wild-type (S6K1+/+) and S6K1-
deficient (S6K1−/−) mice. We have demonstrated that the lack of S6K1 protects against
apoptosis induced by two different stimuli: death receptor activation and trophic factors
withdrawal. Importantly, in vivo S6K1 deficiency protects against fulminant hepatitis
induced by concanavalin A (ConA), a pathological response that depends on TNFR1
González-Rodriguez et al. Page 2
Hepatology. Author manuscript; available in PMC 2010 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
activation. These effects result from the regulation of multiple events involving down-
regulation of key pro-apoptotic mediators of the death-receptor pathway, as well as the
activation of a feed-back loop that dampens the activation of PI 3-K/Akt, a pro-survival
pathway. Therefore, modulation of S6K1 might be critical to overcoming the resistance to
mTOR inhibitors in HCC therapies.
MATERIALS AND METHODS
Immortalized neonatal hepatocyte cell lines were obtained from livers of wild-type
(S6K1+/+) and S6K1−/− mice (12) 3- to 5 days after birth. Hepatocyte apoptosis was
analyzed by flow cytometry, DNA laddering and quantification of cleaved caspases-8 and -3
and their enzymatic activities. ConA was injected in S6K1+/+ and S6K1−/−mice (25 mg/kg)
via the tail vein. After 8 h, livers were removed and samples were fixed in 4%
paraformaldehyde, dehydrated and embedded in paraffin. Sections were stained with
haematoxylin/eosin. Additional experimental procedures are included in the Supplementary
Material.
RESULTS
Generation and characterization of immortalized hepatocyte cell lines from S6K1+/+ and
S6K1−/− mice
Immortalized neonatal hepatocyte cell lines were generated from pooled excised livers from
wild-type (S6K1+/+) or S6K1-deficient (S6K1−/−) mice at postnatal day 3- to 5. Figure 1A
shows the lack of S6K1 protein expression in S6K1−/− immortalized hepatocytes while
levels of LTAg were similar in all cell lines. Cells of both genotypes expressed albumin
(ALB) and carbamoyl phosphate synthase (CPS), indicating phenotypic features of
hepatocytes upon immortalization (Fig. 1B). Moreover, the absence of vimentin (VIM)
staining demonstrated that the maintenance of cell lines in arginine-free medium (5) was
sufficient to eliminate contaminating fibroblasts in the primary culture. Thus, the
characterization of S6K1−/− and S6K1+/+ hepatocytes has demonstrated that this novel
cellular model is physiologically relevant.
Next, we measured the expression of pro- and anti-apoptotic proteins of the intrinsic and
extrinsic apoptotic pathways in growing cells of both genotypes. It is noteworthy that the
expression of caspase-8 and Bid was clearly down-regulated in S6K1−/− hepatocytes, and in
liver extracts of S6K1−/− deficient mice at 3- to 5 days or 10- to 12 weeks after birth, as
compared to their corresponding wild-type controls (Fig. 1C). As shown in Fig. 1D, both
caspase-8 and Bid were down-regulated at the mRNA level indicating that S6K1 is required
for transcription of these genes. By contrast, we did not observe changes in the levels of
other pro- and anti-apoptotic proteins (Supporting Fig.1).
Apoptosis induced by death receptor activation is reduced in S6K1-deficient neonatal
hepatocytes
To investigate the role of S6K1 in the susceptibility to apoptosis, we compared the effect of
death receptor activation in wild-type and S6K1−/− immortalized neonatal hepatocytes.
Cells were stimulated with TNFα in the presence of actinomycin D or with the Fas agonist
Jo2 at the indicated doses for 16 h. Phase-contrast microscopy revealed many wild-type
hepatocytes with morphological characteristics of apoptotic cells. By contrast, only a few
S6K1−/− cells displayed apoptotic phenotype (Fig.2A). Analysis of nuclear morphology
confirmed an increase in the incidence of condensed and/or fragmented nuclei in wild-type
hepatocytes (51 %) in comparison to S6K1−/− cells (<10 %) (Fig. 2B). These results suggest
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that, in immortalized neonatal hepatocytes, there is a direct link between S6K1 expression
and susceptibility to apoptosis upon death receptor activation.
Next, we measured the percentage of cells undergoing apoptosis by quantification of
hypodiploid cells. Treatment with TNFα receptor (TNF-R1) or Fas activators for 16 h
increased the percentage of hypodiploid wild-type, but not S6K1−/− hepatocytes, as
compared to untreated cells (Fig. 2C). Importantly, reconstitution of S6K1 expression
reversed the apoptotic phenotype of S6K1−/− hepatocytes (Supporting Fig. 2A and B).
Moreover, the DNA laddering pattern revealed that S6K1 deficiency decreased the
percentage of apoptotic cells upon death receptor activation (Fig. 2D). Consistent with our
data in immortalized cells, primary hepatocytes from S6K1−/− mice were more resistant to
TNFα plus actinomycin D-induced apoptosis when compared with hepatocytes from wild-
type mice (Fig. 2E). The lack of response of S6K1−/− cells was not due to a general
inhibition of protein synthesis since cycloheximide did not block apoptosis in wild-type
cells. In addition, rapamycin-treated S6K1+/+ cells showed a significant inhibition of
apoptosis induced by death receptor activation (Supporting Fig. 3A and B).
S6K1 deficiency protected neonatal hepatocytes from caspase-8 activation, Bid cleavage
and cytochrome C release by inhibiting JNK-mediated FLIPL degradation
To determine the step in the apoptotic cascade that is blocked as a result of S6K1 deficiency,
we studied the activation of caspase-8 in wild-type and S6K1−/− hepatocytes after Jo2 or
TNFα plus actinomycin D treatment. Consistent with our previous data, cleavage of
caspase-8, which is activated following Fas or TNF–R1 oligomerization (2), was abrogated
in S6K1−/− hepatocytes (Fig. 3A). These results paralleled changes in caspase-8 activity.
Because activation of caspase-8 is a proximal event following activation of the Fas or TNF–
R1 receptors, our data demonstrate that one of the earliest events in death receptor-induced
apoptosis is suppressed in S6K1−/− hepatocytes.
Activation of caspase-8 is modulated by the levels of FLICE inhibitory protein (c-FLIP).
Mouse liver expresses mostly the FLIPL isoform that contains a pseudo-caspase domain and
is therefore a specific caspase-8 inhibitor (13). FLIPL protein degradation is a key event in
FasL and TNFα-induced cell death. FLIPL levels were consistently reduced after 16 h
treatment of wild-type hepatocytes with Jo2 and TNFα plus actinomycin D (Fig. 3B). Of
note, degradation of FLIPL by both apoptotic stimuli was inhibited in S6K1−/− cells. This
was coincident with an increase in phospho-JNK and phospho-c-Jun in TNFα plus
actinomycin D or Jo2–stimulated wild-type hepatocytes, but not in S6K1−/− cells.
Moreover, in S6K1−/− hepatocytes, phosphorylation of JNK and c-Jun was present at higher
levels than in wild-type cells under non-apoptotic conditions. This basal increase may be
due to signaling unrelated to death receptor activation possibly related with increased
developmental stress in S6K1−/− hepatocytes. However, in these cells phosphorylated JNK
remained unchanged upon apoptotic stimulation. Importantly, S6K1 activation, measured by
its phosphorylation at Thr 389 residue, was increased in TNFα plus actinomycin D or Jo2–
stimulated-S6K1+/+ cells.
To further demonstrate that S6K1 expression regulates the susceptibility to death receptor-
mediated apoptosis in hepatocytes at the DISC level, we established siRNA assays. As
depicted in Fig. 3B, S6K1 expression was reduced by 95% in wild-type cells treated with
S6K1 siRNA as compared to the control siRNA. Moreover, reduction of S6K1 in wild-type
hepatocytes abolished JNK phosphorylation and FLIPL degradation upon treatment with
TNFα plus actinomycin D. To investigate whether activation of JNK is required for TNFα
plus actinomycin D-induced apoptosis in S6K1+/+ cells, JNK1/2 expression was reduced
using siRNA. As shown in Supporting Fig.4, FLIPL degradation, activation of caspases-8
and -3 and the percentage of hypodiploid cells were partly reduced by silencing JNK1/2.
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We investigated whether the lack of S6K1 protected neonatal hepatocytes from Bid
cleavage, and whether S6K1 deficiency affected the mitochondrial pathway. Detectable
levels of tBid were observed in Jo2 or TNFα plus actinomycin D-stimulated wild-type
hepatocytes, whereas in S6K1−/− cells tBid was barely detectable (Fig. 4A). Moreover,
BclxL, an anti-apoptotic member of the Bcl2 family with a prominent role in hepatocyte
survival (5,14), was down-regulated in wild-type hepatocytes, but remained at high levels in
S6K1-deficient cells stimulated with death receptor ligands. We next evaluated whether the
release of cytochrome C from mitochondria to the cytosol in response to Jo2 or TNFα plus
actinomycin D was affected by deletion of S6K1. Cytochrome C appeared in the cytosol
after death receptor stimulation in wild-type cells, but not in the absence of S6K1 (Fig. 4B).
Consistent with our previous data, cleavage of the executer caspase-3 following Fas or
TNF–R1 oligomerization was abrogated in S6K1−/− immortalized hepatocytes (Fig. 4A).
These results paralleled changes in caspase-3 activity (Fig. 4C). Moreover, reconstitution of
S6K1 expression in S6K1−/− immortalized hepatocytes reversed the protection against
activation of caspase-3 (Supporting Fig. 2A and D). Of note, primary S6K1−/− hepatocytes,
but not wild-type cells, were protected against activation of caspase-3 upon TNFα plus
actinomycin D treatment, thus ruling out artifactual effects mediated by the immortalization
procedure.
S6K1−/− mice are resistant to Fas and TNFα-dependent fulminant hepatitis
Our finding that the absence of S6K1 protects hepatocytes from Jo2 and TNFα-induced
apoptosis prompted us to analyze this phenomenon in vivo. We asked whether S6K1−/−
mice were resistant to acute liver failure. Con A-induced fulminant hepatitis mimics many
aspects of human acute liver failure including Fas/TNFα-mediated hepatocyte death (15).
Accordingly, mice of both genotypes were injected with ConA (25 mg/kg body weight) via
the tail vein and livers were removed at 8 h post injection. Whereas the livers from wild-type
mice turned dark red following injection, an indication of hepatic hemorrhage, livers from
S6K1−/− mice did not show this effect (results not shown). Histological analysis from the
ConA-injected wild-type mice showed parenchymal necrosis and hemorrhage (Fig. 5A),
whereas livers from the majority of S6K1-null mice showed no pathological histology. As a
measure of death receptor-mediated apoptosis, FLIPL degradation, Bid cleavage and
activation of caspase-3 were detected in the livers of wild-type, but not S6K1−/− mice upon
ConA injection (Fig. 5B, 5C).
S6K1 deficiency confers protection against apoptosis induced by serum withdrawal in
neonatal hepatocytes
Next, we investigated whether S6K1-null hepatocytes were protected against a different
apoptotic trigger such as throphic factor deprivation, which elicits its effect mainly via the
intrinsic pathway (5,14). After 16 h of serum deprivation, most of the S6K1−/− immortalized
hepatocytes remained intact whereas wild-type hepatocytes displayed an apoptotic
phenotype (Fig. 6A). Of note, the appearance of condensed and/or fragmented nuclei was
only visible in wild-type cells upon serum withdrawal (Fig. 6B). In light of these results,
serum withdrawal significantly increased the percentage of hypodiploid cells and the extent
of DNA laddering in a time-dependent manner (Fig. 6C, 6D). Again, reconstitution of S6K1
expression reversed the apoptotic phenotype of S6K1−/− hepatocytes (Supporting Fig. 2A
and B). Importantly, primary hepatocytes prepared from S6K1-null mice were completely
resistant to serum withdrawal-induced apoptosis, when compared with primary hepatocytes
prepared from wild-type mice (Fig. 6E). Moreover, rapamycin significantly decreased the
percentage of apoptotic S6K1+/+ hepatocytes upon serum withdrawal (Supporting Fig 3B).
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S6K1 deficiency provoked an imbalance between pro-apoptotic and anti-apoptotic protein
expression in hepatocytes
To elucidate the molecular basis for reduced apoptosis upon growth-factors deprivation in
S6K1-deficient hepatocytes, we studied the expression of Bim and BclxL, two Bcl2 family
members whose expression is modulated by serum withdrawal in neonatal hepatocytes
(5,6,14). Levels of the pro-apoptotic Bim were low under growth-promoting conditions and
gradually increased in serum-deprived wild-type hepatocytes, but not in S6K1−/− cells. By
contrast, the expression of the anti-apoptotic BclxL was high under growth-promoting
conditions, but gradually decreased after serum deprivation in wild-type but not in S6K1−/−
cells (Fig. 7A). Thus, the BclxL/Bim ratio decreased dramatically in 16 h serum-deprived
wild-type hepatocytes, but remained unchanged in the absence of S6K1. Consequently,
cytochrome C appeared in the cytosol after 16 h of serum withdrawal in wild-type cells. In
contrast, cytochrome C was never detected in the cytosol of S6K1−/− hepatocytes
throughout the period of serum withdrawal (Fig. 7B and results not shown). Finally,
cleavage and enzymatic activity of caspase-3 were increased in serum-deprived
immortalized and primary wild-type hepatocytes, but not in those lacking S6K1 (Figs. 7A,
7C). Importantly, reconstitution of S6K1 expression in S6K1−/− hepatocytes reversed the
protection against serum withdrawal-induced activation of caspase-3 (Supporting Fig. 2A
and D).
S6K1 deficiency resulted in sustained activation of Akt and ERK survival pathways upon
serum withdrawal through the suppression of a negative feed-back loop
Apoptotic triggers fail to affect S6K1−/− neonatal hepatocytes likely due to sustained
activation of Akt and ERK, two major survival pathways in mammalian cells (7,16).
Because Akt is known to act upstream of mTOR/S6K1, one would expect that S6K1
deficiency would not alter its phosphorylation levels. However, in S6K1−/− hepatocytes Akt
remained highly phosphorylated upon 16 h of serum withdrawal whereas no phospho-Akt
was detected in wild-type cells under these conditions (Fig. 8A). Moreover, FOXO1 was
detected in nuclear extracts from serum-deprived wild-type, but not S6K1−/− hepatocytes.
Similarly, sustained phosphorylation of ERK was observed in serum deprived S6K1−/−
hepatocytes as compared to wild-type controls. Of note, a substantial amount of
phosphorylated S6K1 was still present in wild-type hepatocytes upon 16 h of serum
withdrawal. To directly demonstrate that the activation of Akt and ERK was responsible for
the resistance to apoptosis observed in serum-deprived S6K1−/− hepatocytes, we examined
the effect of serum withdrawal combined with LY294002 (LY, PI 3-K/Akt inhibitor) or
PD098059 (PD, MEK inhibitor) for 16 h. As shown in Fig. 8B, serum deprivation in
combination with either LY or PD increased by twofold the percentage of apoptotic
S6K1−/− hepatocytes. Moreover, the combination of both compounds increased the
percentage of S6K1−/− apoptotic cells to levels similar to those seen in serum-deprived
wild-type cells (Fig. 6C).
Because the phosphorylation of insulin receptor substrate-1 (IRS-1) is a common molecular
event that leads to Akt and ERK phosphorylation (17), we investigated its tyrosine
phosphorylation in serum-deprived cells of both genotypes. As depicted in Fig. 8C, IRS-1
tyrosine phosphorylation was high in wild-type hepatocytes under growth-promoting
conditions and decreased dramatically upon growth factors withdrawal. Conversely,
S6K1−/− cells retained IRS-1 tyrosine phosphorylation even after long-term (16 h) serum
deprivation. Under these conditions, the activation of PI 3-K paralleled IRS-1 tyrosine
phosphorylation in both cell types. Finally, since S6K1 is an IRS-1 serine kinase (17), we
analyzed the status of IRS-1 ser-307 phosphorylation under apoptotic and non-apoptotic
conditions. IRS-1 ser-307 phosphorylation was detectable in wild-type hepatocytes growing
in 10% FS and was slightly decreased under serum deprivation (Fig. 8C). Conversely, in
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S6K1−/− hepatocytes IRS-1 ser- 307 phosphorylation was absent in both growth-promoting
and serum-free conditions.
Protection of wild-type hepatocytes against serum withdrawal-induced cell death by
siRNA-mediated reduction of S6K1
To confirm that S6K1 expression regulates the susceptibility of neonatal hepatocytes to
apoptotic signals upon growth factor deprivation, we performed siRNA assays. As depicted
in Supporting Fig. 5, silencing of S6K1 in neonatal hepatocytes reduced the percentage of
hypodiploid cells. In addition, it significantly decreased caspase-3 activity detected upon
serum withdrawal. Importantly, in siRNA-treated hepatocytes, phosphorylation of Akt and
ERK were maintained at higher levels than in the controls, and this effect occurred in
parallel with a markedly lower level of IRS-1 serine-307 phosphorylation. Thus, removal of
S6K1 elicits a survival effect in serum-deprived hepatocytes.
DISCUSSION
Among the survival pathways triggered by tyrosine kinase growth factors, mTOR has
emerged as a therapeutic target for HCC due to the fact that mTOR/S6K1 signaling plays an
important role in angiogenesis, cell cycle progression, and proliferation of liver cancer cells
(18). In this regard, over expression of the activated phosphorylated form of mTOR was
observed in 15% of human HCCs and increased expression of S6K1 was found in 45% of
cases and was positively correlated with tumor size (11). To date, systemic
chemotherapeutic treatment is ineffective against HCC (19), in part due to the apoptosis
resistance observed in HCC cells. This is particularly relevant in therapies with mTOR
inhibitors because it has been shown that rapamycin suppresses the feed-back loop that
dampens the activation of Akt, a pro-survival intermediate (20). In light of these findings,
loss of the tuberous sclerosis complex genes (TSC1 or TSC2) leads to constitutive activation
of mTORC1 pathway which confers resistance to insulin-induced activation of PI 3-K and
Akt (21). Although genetic studies have contributed to the discovery of several cytoplasmic
modulators of hepatocyte survival, the specific role of S6K1 in the complex signaling
networks controlling the balance between death and survival in liver cells has not been
investigated. To address this important issue, we have explored the mechanism of cell death
in immortalized hepatocyte cell lines generated from wild-type and S6K1-deficient mice.
This cellular model has provided insight regarding the molecular mechanism of S6K1
deficiency in modulating the susceptibility of hepatocytes to apoptotic triggers including
death receptor activation (mediated by the extrinsic pathway) or growth factor withdrawal
(mediated by the intrinsic pathway).
Unexpectedly, we have found that the lack of S6K1 confers protection against apoptosis
induced by TNFα plus actinomycin or Jo2 in both immortalized and primary hepatocytes,
ruling out the possibility of collateral effects due to the immortalization protocol. In the light
of these results, S6K1 is activated by these apoptotic triggers in wild-type cells. Moreover,
rapamycin significantly inhibited death receptor-induced apoptosis in S6K1+/+ hepatocytes.
At the molecular level, FLIPL degradation and, subsequently, caspase-8 cleavage and its
activation were absent in TNFα plus actinomycin or Jo2-treated S6K1−/− hepatocytes,
indicating that this protection was elicited at the DISC, an early event in the death-receptor
apoptotic pathway, despite the reduced expression of downstream intermediates such as
caspase-8 and Bid. Thus, subsequent molecular events of the apoptotic program, such as
cytochrome C release from the mitochondria, activation of the executer caspase-3 and,
finally, DNA laddering were totally abolished in S6K1-null hepatocytes. Interestingly,
protection against FLIPL degradation upon TNFα̣ plus cycloheximide treatment has recently
been reported by Chang and co-workers (22) in fibroblasts lacking JNK1 or the ubiquitin
ligase Itch. Thus, one possibility to explain our results could be the absence of JNK1-
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mediated Itch phosphorylation in S6K1-deficient hepatocytes, resulting in the prevention of
FLIPL degradation and the subsequent caspase-8-mediated Bid cleavage. Although our
results show the absence of modulation of JNK phosphorylation in S6K1−/− hepatocytes
upon TNFα plus actinomycin D or Jo2 treatment, the fact that silencing of JNK1/2 in
S6K1+/+ cells did not totally prevent apoptosis induced by these stimuli indicates that JNK-
independent signaling might also mediate death receptor-induced apoptosis in hepatocytes
as recently suggested (23). On the other hand, it has been reported that in hepatocytes PI 3-
K/Akt signaling activated by HGF-Met coupling ensures high levels of FLIPL and that is a
critical step in the protection against its degradation by Fas (24). However, TNFα plus
actinomycin or Jo2 treatments did not decrease Akt or ERK phosphorylation in either kind
of cells (results not shown) excluding this mechanism in S6K1 deficiency-induced
protection against apoptosis. Moreover, in S6K1−/− hepatocytes, protection against death
receptor-mediated apoptosis correlated with the maintenance of high levels of the anti-
apoptotic protein BclxL compared to wild-type cells. These data are in agreement with our
previous findings in PTP1B−/− hepatocytes showing a positive correlation between BclxL
levels and cell survival (14). Accordingly, the maintenance of high levels of FLIPL and
BclxL during stimulation with death receptor ligands confers protection against apoptosis in
S6K1-deficient hepatocytes. It remains to be determined exactly where S6K1 downstream
signaling interferes with anti-apoptotic gene expression. Nevertheless, the importance of
these molecular events have been confirmed in a pathophysiologycally relevant in vivo
model in which we showed that S6K1 deficiency protects against acute liver failure
associated with hepatocytes apoptosis provoked by ConA injection. Thus, modulation of
specific pathways preventing the formation of the FADD-containing complex II in TNF-R1
signaling (1) could have a clinical impact and be more selective in preventing hepatocytes
death. In this regard the use of inhibitors of S6K1 could have clinical benefits.
As stated above, in liver cells, trophic factors promote survival mainly through the activation
of the tyrosine kinase receptor signaling which, among other pathways, results in the
activation of mTOR/S6K1 (20). When we investigated the impact of S6K1 deficiency on the
susceptibility to apoptosis triggered by growth factors withdrawal we unexpectedly found
that S6K1−/− hepatocytes, either immortalized or primary cultured cells, were refractory to
apoptosis induced by serum deprivation. At the molecular level, the BclxL/Bim ration was
significantly higher in serum-deprived S6K1−/− hepatocytes than in the controls. These
results clearly indicate that S6K1 levels modulate the balance between the expression of
these anti-apoptotic (BclxL) and pro-apoptotic (Bim) proteins in response to serum
withdrawal, which may influence the subsequent cellular events leading to mitochondrial
membrane permeabilization, cytochrome C release, caspase-3 activation, DNA
fragmentation and cell death. These results, combined with those discussed below, strongly
suggest that S6K1 expression must be tightly controlled during liver development, as a
defect in this protein affects hepatocyte's susceptibility to apoptotic signals.
Previous investigations in immortalized hepatocytes cultured under serum-free conditions
showed the gradual dephosphorylation of Akt in parallel with FOXO1 entry into the nucleus
(14). Of note, nuclear FOXO1 binds to promoters of target genes that induce cell death
including Bim (25) and BCL-6, a transcriptional repressor of BclxL (14), indicating that
nuclear FOXO1 controls the BclxL/Bim ratio. Surprisingly, in serum-deprived S6K1−/−
hepatocytes the phosphorylation of Akt remained high and FOXO1 was not detected in the
nucleus. Altogether our data indicate that under serum-free conditions, S6K1 deficiency in
hepatocytes maintains activated survival signaling pathways, resulting in protection against
cell death.
As stated above, the possibility that S6K1 might be the crucial molecule responsible for the
negative feed-back mechanism that reaches the cell membrane and switches off receptor
González-Rodriguez et al. Page 8
Hepatology. Author manuscript; available in PMC 2010 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
tyrosine kinase growth factor signaling has been proposed in previous studies performed
with rapamycin-treated cells (26). However, the present study provides the first evidence
demonstrating that S6K1 directly modulates this mechanism in hepatocytes. In this regard,
our results clearly show a remnant activation of S6K1 in serum-deprived wild-type
hepatocytes that probably abrogates the activation of Akt and ERK. Thus, S6K1 deficiency
releases the negative feed-back inhibition of Akt and ERK activities, antagonizing apoptosis
by promoting the phosphorylation of both survival pathways. This molecular mechanism
might be critical in the liver, where it could have impact in serious pathological states such
as hepatitis, HCC and acute liver failure (18).
IRS-1 is the common upstream mediator of Akt and ERK activation (17). In our study high
levels of phosphorylated IRS-1 in Ser-307 were observed in wild-type hepatocytes in
parallel with low levels of its tyrosine phosphorylation under apoptosis-inducing serum-free
conditions. The result was the inhibition of the downstream signaling pathways mediated by
PI 3-K/Akt and Grb-2/Ras/ERK that trigger hepatocyte survival (5,6). By contrast, IRS-1
Ser-307 phosphorylation was virtually absent in S6K1 null hepatocytes or in wild-type cells
with reduced levels of S6K1 induced by siRNA, resulting in its sustained tyrosine
phosphorylation and, subsequently, in the activation of PI 3-K/Akt and ERK. Importantly,
the pharmacological inhibition of either PI 3-K/Akt or MEK resulted in a modest induction
of apoptosis in S6K1−/− hepatocytes. However the combination of both compounds
significantly abrogated the survival effect of S6K1 deficiency. These results indicate that, at
least in hepatocytes, both Akt and ERK signaling needs to be disrupted to release the
survival effect elicited by S6K1 inhibition. Thus, our data have important pharmacological
implications. First, the specific inhibition of S6K1 by rapamycin and its derivates augments
Akt and ERK signaling, which might promote tumor survival. Second, from a therapeutic
point of view, our findings suggest that the combination of rapamycin-like compounds with
inhibitors of Akt and ERK could bypass the feed-back mechanisms that confer protection
against survival.
In summary our results demonstrated that specific inhibition of S6K1 in hepatocytes confers
protection against apoptosis induced by the extrinsic or the intrinsic apoptotic pathways. A
common molecular event is the maintenance of BclxL expression in S6K1−/− hepatocytes
under apoptotic stimuli, resulting in the protection against acute liver failure and the
enhancement of survival against death receptor ligands or withdrawal of throphic factors.
This mechanism might explain the resistance to mTOR inhibitors in cancer treatments and
strongly suggests that S6K1 inhibition could be beneficial in preventing acute liver failure
and, in combination with inhibitors that abrogate the sustained activation of Akt and ERK,
could improve the efficacy of HCC treatment.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Generation and characterization of immortalized hepatocyte cell lines from S6K1+/+
and S6K1−/− mice
A. S6K1+/+ and S6K1−/− immortalized hepatocytes cultured under growth-promoting
conditions (DMEM plus 10% FS) were lysed and S6K1 and LTAg expression of three
independent cell lines from each genotype was analyzed in whole-cell lysates by western
blot. The anti-β̣-actin antibody was used as a loading control. B. Immunofluorescence
detection of albumin (ALB), carbamoyl phophate synthetase (CPS) and vimentin (VIM) of
growing S6K1+/+ and S6K1−/− immortalized neonatal hepatocytes. As a negative control for
ALB and CPS antibodies, immortalized beta cells were used for immunofluorescence. As a
positive control for VIM, mouse embryo fibroblasts were used. Representative images are
shown. ALB and CPS were also analyzed by western blot. C. Liver extracts from 6- to 8
neonatal (3- to 5 days-old) and adult mice (10- to 12 weeks-old) of each genotype (S6K1+/+
and S6K1−/−), and cell lysates from S6K1+/+ and S6K1−/− immortalized hepatocytes
cultured under growth-promoting conditions (DMEM plus 10% FS) were analyzed by
western blot with the antibodies against Bid and caspase-8. The anti-β̣-actin antibody was
used as a loading control. A representative experiment is shown. D. RNA was isolated from
livers of S6K1+/+ and S6K1−/− neonatal and adult mice and S6K1+/+ and S6K1−/−
immortalized neonatal hepatocytes. Bid and caspase-8 mRNA levels were determined by
real-time PCR. The value of wild-type condition was set to 100%. Results are expressed as
percentage of decrease of caspase-8 and Bid mRNA and are means ±SE. Statistical
significance was carried out by Student's t test comparing the S6K1−/− values with the
respective values of wild-type controls. *p<0.05 was considered significant.
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Figure 2. Apoptosis induced by death receptor activation was reverted in S6K1-deficient
neonatal hepatocytes
S6K1+/+ and S6K1−/− immortalized hepatocytes were stimulated with TNFα (30 ng/ml) plus
actinomycin D (100 ng/ml) (T+A) or Jo2 (2 μg/ml), for 16 h in DMEM plus 5% FS. A.
Representative phase-contrast micrographs of S6K1+/+ and S6K1−/− hepatocytes after
apoptotic stimuli. B. Representative images of the nuclear morphology of untreated and
treated S6K1+/+ and S6K1−/− hepatocytes after staining of DNA with DAPI and
visualization by fluorescence microscopy. C. The percentage of cells with DNA lower than
2C (apoptotic cells) was determined by flow cytometry. Results are means ±SE. Statistical
significance was determined by Student's t test comparing the S6K1−/− condition with the
respective values for wild-type controls. *p<0.05 was considered significant. D.
Extranuclear DNA obtained from untreated and treated S6K1+/+ and S6K1−/− hepatocytes
was electrophoresed and visualized by UV fluorescence. A representative experiment is
shown. E. Representative phase-contrast micrographs of S6K1+/+ and S6K1−/− primary
hepatocytes after exposure to the apoptotic stimuli TNFα (30 ng/ml) plus actinomycin D
(100 ng/ml) (T+A) for 16 h.
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Figure 3. S6K1 deficiency protected neonatal hepatocytes from caspase-8 activation by inhibiting
JNK-mediated FLIPL degradation
S6K1+/+ and S6K1−/− immortalized hepatocytes were stimulated with TNFα (30 ng/ml) plus
actinomycin D (100 ng/ml) (T+A) or Jo2 (2 μg/ml) for 16 h in DMEM plus 5% FS. A. (left
panel) Total protein (50 μg) was used for western blot analysis with the corresponding
antibodies against caspase-8 and anti-β̣-actin as a control for protein loading. A
representative experiment is shown. (right panel) S6K1+/+ and S6K1−/− immortalized
hepatocytes were treated as described above and caspase-8 enzymatic activity was
measured. Results are expressed as fold increase of caspase-8 enzymatic activity compared
to the S6K1+/+ condition, which was arbitrarily assigned a value of 1, and are expressed as
means ± SE from three independent experiments. Statistical significance was determined by
Student's t test comparing the S6K1−/− condition with respective values for wild-type
controls. *p<0.05 was considered significant. B. (left panel) Apoptosis was induced as
described in A. Total protein (50 μg) was used for western blot analysis with the
corresponding antibodies against FLIP, phospho-JNK (Thr183/Tyr185), total JNK, phospho-
c-Jun (Ser73), total c-Jun, phospho-S6K1 (Thr 389) and total S6K1. A representative
experiment is shown. (right panel) S6K1+/+ immortalized hepatocytes were seeded in 6 cm
dishes and incubated overnight at 37°C with 5% CO2. When 40- to 50% confluence was
reached, cells were transfected with 100 nM of control or siRNA oligos following
DharmaFECT General Transfection Protocol. After 48 h, hepatocytes were treated as
described above. Then, cells were collected and cell lysates were analyzed by western blot
with the indicated antibodies. Representative autoradiograms are shown.
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Figure 4. S6K1 deficiency protects neonatal hepatocytes from Bid cleavage and prevents
movement of cytochrome C from mitochondria to cytosol
A. S6K1+/+ and S6K1−/− immortalized hepatocytes were stimulated with TNFα (30 ng/ml)
plus actinomycin D (100 ng/ml) (T+A) or Jo2 (2 μg/ml) for 16 h in DMEM plus 5% FS. A.
Total protein (50 μg) was used for western blot analysis with the corresponding antibodies
against Bid, BclxL, active caspase-3 and anti-β̣-actin as a protein loading control. A
representative experiment is shown. B. Mitochondria were separated from the cytosol and
cytochrome C content in the cytosolic fraction was analyzed by western blot. Protein
loading was visualized with the anti-p85α antibody. A representative experiment is shown.
C. S6K1+/+ and S6K1−/− immortalized and primary hepatocytes were treated as described
above and caspase-3 enzymatic activity was measured. Results are expressed as fold change
of caspase-3 enzymatic activity compared to the S6K1+/+ condition, which was arbitrarily
assigned a value of 1, and are expressed as means ± SE from three independent experiments.
Statistical significance was determined by Student's t test comparing the S6K1−/− condition
with the respective values for wild-type controls. *p<0.05 was considered significant.
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Figure 5. Deletion of S6K1 protects against ConA-induced liver failure
A. S6K1+/+ and S6K1−/− adult mice were injected with ConA or with PBS. After 8 h, livers
were removed and fixed. Paraffin sections of liver tissue were stained with haematoxylin
and eosin. B. Liver extracts from S6K1+/+ and S6K1−/− adult mice injected with Con A or
with PBS were prepared. Total protein (50 μg) was used for western blot analysis with the
corresponding antibodies against FLIP and Bid. The anti-β̣-actin antibody was used as a
loading control. A representative experiment is shown. The autoradiograms showing FLIPL
levels and Bid cleavage from 4-6 control or ConA-injected mice of each genotype were
quantitated by scanning densitometry. Results are expressed as arbitrary units and are means
± SE. Statistical significance was carried out by Student's t test by comparison between
wild-type and S6K1−/− mice. *p<0.05 was considered significant. C. Caspase-3 enzymatic
activitiy was measured in liver extracts analyzed in B. Results are expressed as fold increase
of enzymatic activity compared to the S6K1+/+ condition, which was arbitrary assigned a
value of 1, and are means ± SE from 3-4 liver extracts of each genotype. Statistical
significance was determined by Student's t test comparing the S6K1−/− condition with the
respective values for wild-type controls. *p<0.05 was considered significant.
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Figure 6. Protection against growth factor withdrawal-induced apoptosis in S6K1-deficient
hepatocytes
S6K1+/+ and S6K1−/− immortalized hepatocytes were incubated in serum-free medium for 8
and 16 h. A. Representative phase-contrast microscopy images of S6K1+/+ and S6K1−/−
hepatocytes after 16 h of serum withdrawal. B. Representative images of nuclear
morphology of untreated and treated S6K1+/+ and S6K1−/− hepatocytes after staining of
DNA with DAPI and analysis by fluorescence microscopy. C. The percentage of cells with
DNA lower than 2C (apoptotic cells) was determined by flow cytometry Results are
expressed as percentage of apoptotic cells are means ± SE. Statistical significance was
determined by Student's t test comparing the S6K1−/− condition with the respective values
for wild-type controls. *p<0.05 was considered significant. D. Extranuclear DNA, obtained
from untreated and treated S6K1+/+ and S6K1−/− hepatocytes, was electrophoresed and
visualized by UV fluorescence. A representative experiment is shown. E. Representative
phase-contrast micrographs of S6K1+/+ and S6K1−/− primary hepatocytes after 16 h of
serum withdrawal.
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Figure 7. S6K1 deficiency protected neonatal hepatocytes from cytochrome C release and
caspase-3 activation upon serum withdrawal
S6K1+/+ and S6K1−/− immortalized hepatocytes were incubated in serum-free medium for 8
and 16 h. A. (left panel)Total protein (50 μg) was used for western blot analysis with the
corresponding antibodies against Bim, BclxL and active caspase-3. The anti-β̣-actin antibody
was used as a loading control. A representative experiment is shown. The autoradiograms
corresponding to three independent experiments were quantitated by scanning densitometry
and the BclxL/Bim ratio was calculated. Results are expressed in arbitrary units. Statistical
significance was determined by Student's t test. *p<0.05 was considered significant (right
panel). B. Mitochondria were separated from cytosol and cytochrome C content was
analyzed in the cytosolic fraction by western blot. The anti-p85α antibody was used as a
loading control. A representative experiment is shown. C. S6K1+/+ and S6K1−/− primary
and immortalized hepatocytes were treated as described above and caspase-3 enzymatic
activity was measured. Results are expressed as fold increase of enzymatic activity as
compared to the S6K1+/+ condition, which was arbitrary assigned a value of 1, and are
means ± SE from three independent experiments. Statistical significance was determined by
Student's t test. *p<0.05 was considered significant.
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Figure 8. Survival pathways remain intact in S6K1-deficient hepatocytes upon growth factors
withdrawal
S6K1+/+ and S6K1−/− immortalized hepatocytes were incubated in serum-free medium for 8
and 16 h. A. At the end of the culture time, attached and non-attached cells were collected
and total cell lysates and nuclear extracts were prepared. (upper panel) Total protein (50 μg)
was used for western blot analysis with the corresponding antibodies against phospho-Akt
(Ser 473), total Akt, phospho-ERK1/2 (Thr 202/Tyr 204), total ERK1/2, phospho-S6K1 (Thr
389) and total S6K1. (Lower panel) Nuclear protein (50 μg) was submitted to western blot
analysis with the anti-FOXO1 antibody and the anti-nucleolin antibody as a loading control.
A representative experiment is shown. B. S6K1-deficient hepatocytes were treated with LY
294002 (40 μM) and PD 098059 (20 μM), alone or in combination with serum-free medium
for 16 h. The percentage of cells with DNA lower than 2C (apoptotic cells) was determined
by flow cytometry as described in Materials and Methods. Statistical significance was
performed by Student's t test comparing the values of S6K1−/− hepatocytes cultured in
serum-free medium plus LY, PD or LY plus PD with the respective values of S6K1−/− cells
cultured in serum-free medium. *p<0.05 was considered significant. C. Apotosis was
induced as described above. (Upper panel) At the end of the culture time, cells were lysed
and 600 μg of total protein were immunoprecipitated with anti-IRS-1 antibody, and analyzed
by western blot with anti-pTyr or used for an in vitro PI 3-K assay. The conversion of PI to
PIP3 in the presence of [γ32-P] ATP was analyzed by TLC (left panel). (Lowert panel) Total
protein (50 μg) was used for western blot analysis with the corresponding antibodies anti-
phospho-IRS-1 (Ser307), anti-total IRS-1, anti-phospho-Akt (Ser 473) and anti-Akt. The
anti-β̣-actin antibody was used as a loading control (right panel). Representative
autorradiograms are shown.
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